期刊文献+

益赛普治疗前后强直性脊柱炎患者血液流变学指标和血清免疫球蛋白水平变化 被引量:2

下载PDF
导出
摘要 目的:观察强直性脊柱炎(AS)患者经益赛普治疗三个月前后血液流变学指标和IgA、IgG、IgM的变化。方法:291例AS患者采用益赛普注射液皮下注射治疗三个月,治疗前后分别检测患者血液流变学指标和血清免疫球蛋白(IgG、IgA、IgM)水平,并对两次结果进行对比分析。结果:AS患者经益赛普治疗后,高、中、低切变率全血粘度、血浆粘度、红细胞压积、红细胞聚集指数、纤维蛋白原、ESR和血清IgG、IgA、IgM均有不同程度降低,与治疗前比较有显著性差异(P<0.05)。结论:益赛普治疗可使AS患者血液流变学指标和血清免疫球蛋白水平得到很大改善,对缓解临床症状,恢复机体功能有积极意义。
作者 刘波 温娅丽
出处 《微循环学杂志》 2011年第2期32-33,I0001,共3页 Chinese Journal of Microcirculation
  • 相关文献

参考文献9

  • 1姜国平,李慧颖,吕英春,陈琳,韩梅.益赛普治疗强直性脊柱炎临床疗效观察[J].吉林医学,2008,29(21):1897-1898. 被引量:12
  • 2沙洪,张岚,肖诚,李桂琴,黄小杰,王萍,赵静波,李平.探讨和分析强直性脊柱炎患者血液流变学指标的异常[J].中国血液流变学杂志,2007,17(3):425-426. 被引量:11
  • 3Crew MD,Effros RB,Walford RL,et al.Transgenic mice expressing a truncated peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitls.J Interferon Cytokine Res,1998,18(4):219-225.
  • 4Francois RJ,Neure L,Sieper J,et al.Immunohistological examination of open sacroiliacbiopsies of patients with ankylosing spondylitis:detection of tumor necrosis factor-α in two patients with early disease and transforming growth factor β in three more advanced cases.Ann Rheum Dis,2006,65(6):713-720.
  • 5Braun J,van der HD.Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.Expret Opin Investing Drugs,2003,12(7):1 097-1 109.
  • 6黄烽,邓小虎,张亚美,古洁若,鲍春德,张江林,胡大伟,林智明,杨春花,梁东风,郭军华,廖泽涛.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗强直性脊柱炎的多中心双盲随机对照临床研究[J].中华风湿病学杂志,2008,12(5):314-320. 被引量:56
  • 7Gorman JD,Sack K,Davis JJ.Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.N Engl J Med,2002,346(18):1 349-1 356.
  • 8Reed MR,Taylor AL.Tumour necrosis factor inhibitors in ankylosing spondylitis.Intern Med J,2008,38(10):781-789.
  • 9Calin A,Dijkmans BAC,Emery P,et al.Outecmes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.Ann Rheum Dis,2004,63(12):1 594-1 600.

二级参考文献33

  • 1沙洪,张志远,仝小林.糖尿病合并脑梗死、肾功能衰竭患者血液流变学指标的观察[J].中国血液流变学杂志,2005,15(3):454-455. 被引量:1
  • 2董青,杨达人,刘华.HLA-B27阳性强直性脊柱炎患者免疫功能和血液流变学的检测[J].中国血液流变学杂志,2006,16(2):273-274. 被引量:10
  • 3Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index [ J ]. J Rheumato 1, 1994, 21: 2286.
  • 4Mander M, Simpson JM, McLellan A, et al. Studies with an enthesis index as a method of elinieal assessment in ankylosing spondylitls[J]. Ann Rheum Dis, 1987, 46: 197.
  • 5Scott DL, van Riel PL, van derHeijde D, et al. Assessing disease activity in rheumatoid arthritis [ M]. In: The EULAR handbook of standard methods. 2nd ed. Uppsala: Pharmaeia Graphic Communications, 1995 : 204.
  • 6Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index [ J ]. J Rheumatol, 1994,21 : 2281.
  • 7Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spina lmobility in ankylosing spondylitis. The Bath AS Metrology Index[J]. J Rheumatol, 1994, 21 : 1694.
  • 8Ware JE Jr, Sherbourne CD. The MOS 36 - item short - form health survey (SF- 36). I. Conceptual framework and item selection[J]. Med Care, 1992, 30: 473.
  • 9Anderson JJ, Baron G, vander tteijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short - term improvement in ankylosing spondylitis [ J ]. Arthritis Rheum, 2001, 44: 1876.
  • 10Bostan EE, Borman P, Boclur H, et al. Functional disability and quality of life in patients with ankylosing spondylitis [ J ]. Rheumatol Int, 2003,23: 121.

共引文献73

同被引文献23

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部